Fig. 4From: Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trialsPooled analysis for percent changes in HDL-C following evolocumab treatments stratified by dosages versus placebo at 12 weeks follow-up. EVO, evolocumab; PBO, placebo. HDL-C, high-density lipoprotein cholesterolBack to article page